01
Cash & equivalents increased 62.8%
Cash & equivalents changed +62.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$31.2M→$50.8MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSpero Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +62.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -461.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed -306.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SPRO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-346855SEC ↗10-QAug 12, 2026Period Jun 30, 20260001193125-26-346795SEC ↗4Aug 6, 2026Period Aug 3, 20260001807743-26-000007SEC ↗8-KJul 14, 2026Period Jul 8, 20260001193125-26-302473SEC ↗4Jun 25, 2026Period Jun 23, 20260001193125-26-283245SEC ↗4Jun 25, 2026Period Jun 23, 20260001193125-26-283238SEC ↗4Jun 25, 2026Period Jun 23, 20260001193125-26-283230SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -67.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Revenue changed +0.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +15.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-283226